Peptide Comparisons
The head-to-head questions everyone asks, answered with mechanisms and data instead of vendor copy.
BPC-157 vs TB-500
These two are less rivals than teammates. BPC-157 is studied for localized, tissue-specific repair — tendons, ligaments, gut lining — with small daily doses. TB-500 works systemically through actin regulation and cell migration, dosed in milligrams once or twice a week. If forced to pick one for a specific tendon issue, community protocols usually start with BPC-157; for widespread soreness or slow general recovery, TB-500. In practice the most common protocol is both together.
Semaglutide vs Tirzepatide
Head-to-head trial data (SURMOUNT-5) gives tirzepatide the edge on raw weight loss — roughly 20% versus 14% body weight over 72 weeks — thanks to its dual GIP/GLP-1 action. Semaglutide counters with a longer safety track record, more prescriber familiarity, and often better availability. Many people also simply respond differently to each: non-responders on one sometimes do well on the other.
Tirzepatide vs Retatrutide
Retatrutide posted the most dramatic weight-loss numbers ever seen in a trial — around 24% at 48 weeks in phase 2 — by adding glucagon receptor activity (energy expenditure) to tirzepatide's GIP/GLP-1 combination. But tirzepatide is an approved medicine with years of real-world safety data; retatrutide is still in trials, so everything circulating outside them is unverified research material. On evidence-to-risk ratio, tirzepatide remains the sane default; retatrutide is the frontier.
BPC-157 vs Pentadeca Arginate (PDA)
Pentadeca Arginate is the same 15-amino-acid sequence as BPC-157 delivered as an arginate salt — it exists primarily because US compounding pharmacies needed a version they could keep offering after the FDA moved BPC-157 onto its bulk-substances difficulty list in 2023. Functionally, community reports and vendor positioning treat them as interchangeable, with identical dosing. If you have legitimate access to one and not the other, that's the deciding factor; there is no evidence either direction that one outperforms.
Ipamorelin vs Sermorelin
They pull the same growth-hormone lever from opposite sides. Sermorelin is a GHRH analog — it whispers to the pituitary through the 'release now' pathway and is the version wellness clinics have prescribed for decades. Ipamorelin is a ghrelin-mimetic secretagogue — a different receptor — prized for triggering a clean GH pulse without cortisol or appetite side effects. Alone, sermorelin is the clinically familiar choice; but the modern standard is ipamorelin combined with a GHRH analog, because hitting both receptors together is synergistic rather than additive.
CJC-1295 DAC vs CJC-1295 (no DAC)
One molecule, two completely different tools. Without DAC (Mod GRF 1-29), half-life is ~30 minutes: you get a sharp, natural-shaped GH pulse, timed to your injection, dosed 100 mcg one to three times daily alongside a secretagogue. With DAC, half-life stretches to about a week: GH sits moderately elevated around the clock — the 'GH bleed' — from a single 1–2 mg weekly shot. Purists favor no-DAC for mimicking physiology; convenience favors DAC. Neither is 'stronger'; they are different shapes of the same exposure.
GHRP-2 vs GHRP-6
GHRP-2 releases somewhat more GH per microgram; GHRP-6 triggers dramatically more hunger through stronger ghrelin mimicry. That hunger is the real decision point: for someone force-feeding a bulk, GHRP-6's appetite surge is a feature; for everyone else it's the reason these are legacy compounds. Both nudge cortisol and prolactin at higher doses — the flaw that ipamorelin was designed to eliminate. In 2026, the honest answer to 'which one?' is usually 'ipamorelin instead,' unless the hunger effect itself is what you're after.
Ipamorelin vs Hexarelin
Hexarelin is the strongest GH secretagogue per microgram in common use — and the least forgiving. It desensitizes its own receptor within weeks of continuous use and measurably bumps cortisol and prolactin. Ipamorelin releases less GH per shot but does it silently and sustainably, cycle after cycle. Unless a protocol has a specific, short-term reason to want maximum pulse amplitude (some research interest centers on hexarelin's cardiac effects), ipamorelin is the rational default.
Semax vs Selank
Same Russian research lineage, opposite temperaments. Semax is the accelerator: an ACTH(4-10) analog studied for focus, processing speed and BDNF elevation — users describe it as stimulating without being a stimulant. Selank is the brake: a tuftsin analog with anti-anxiety effects compared in Russian trials to benzodiazepines, minus sedation and dependence. Pick by your bottleneck — scattered focus points to Semax, anxious rumination points to Selank — and know that many protocols simply alternate: Semax for work hours, Selank for evenings or high-stress days.
PT-141 vs Melanotan II
PT-141 literally descends from Melanotan II — it's a metabolite refined into an FDA-approved drug (Vyleesi) for sexual desire, shedding most of the tanning activity along the way. MT2 remains the tanning compound, with libido effects as a famous side effect and more nausea/flushing baggage. Choose by goal, not potency: tanning → MT2; libido on demand → PT-141. Using MT2 for libido means accepting darkening skin and mole changes as the cost.
AOD-9604 vs HGH Fragment 176-191
These are near-twins: both are the lipolytic tail (176-191 region) of the growth hormone molecule, isolated so fat metabolism comes without GH's growth or glucose effects. AOD-9604 is Fragment 176-191 plus one added tyrosine for stability — and it's the only one of the pair with a human trial history (obesity trials in the 2000s, which showed modest results and were shelved commercially). Practical differences are small; AOD's oral/injectable flexibility and trial data give it the slight edge in credibility, while plain Frag is typically cheaper.
Sermorelin vs Tesamorelin
Both are GHRH analogs, but they live in different evidence classes. Tesamorelin is FDA-approved (Egrifta), with human trials showing real visceral-fat reduction at 2 mg daily — the strongest clinical evidence of any GH-axis peptide. Sermorelin is the affordable clinic staple: decades of prescribing history, flexible dosing, a fraction of the cost, but no comparable outcome trials. If targeting stubborn visceral/abdominal fat with maximum evidence, tesamorelin earns its price. For general GH-axis support on a budget, sermorelin remains the entry point.